EUCTR2021-004327-32-GR进行中（未招募）1 期
A Phase III, Randomized, Doubleblind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Nonsmall Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinumbased Concurrent Chemoradiation Therapy (PACIFIC-8) - PACIFIC-8
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,570
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant must be = 18 years at the time of screening.
- •2. Histologically- or cytologically-documented NSCLC and have been treated with concurrent CRT for locally advanced, unresectable (Stage III) disease
- •3. Provision of a tumour tissue sample obtained prior to CRT
- •4. Documented tumour PD-L1 status = 1% by central lab
- •5. Documented EGFR and ALK wild-type status (local or central).
- •6. Patients must not have progressed following definitive, platinum-based, concurrent chemoradiotherapy
- •7. Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy
- •8. Participants must have received a total dose of radiation of 60 Gy ±10% (54 Gy to 66 Gy) as part of the chemoradiation therapy, to be randomised. Radiation therapy should be administered by intensity modulated RT (preferred) or 3D-conforming technique.
- •9. WHO performance status of 0 or 1 at randomization
- •10. Adequate organ and marrow function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 942
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 628
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •1. History of another primary malignancy except for malignancy treated with curative intent with no known active disease = 5 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include adequately resected non-melanoma skin, cancer and curatively treated in situ disease, or adequately treated carcinoma in situ or Ta tumours treated with curative intent and without evidence of disease.
- •2. Mixed small cell and non-small cell lung cancer histology.
- •3. Participants who receive sequential (not inclusive of induction) chemoradiation therapy for locally advanced (Stage III) unresectable NSCLC.
- •4. Participants with locally advanced (Stage III) unresectable NSCLC who have progressed during platinum-based cCRT.
- •5. Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy (excluding alopecia).
- •6. Participants with =grade 2 pneumonitis from prior chemoradiation therapy.
- •7. History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, or idiopathic pneumonitis regardless of time of onset prior to randomisation. Evidence of active non-CRT induced pneumonitis, (= Grade 2), active pneumonia, active ILD, active or recently treated pleural effusion, or current pulmonary fibrosis.
- •8. Active or prior documented autoimmune or inflammatory disorders (with exceptions)
- •9. Active EBV infection, or known or suspected chronic active EBV infection at screening
- •10. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone.MedDRA version: 18.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 Diabetes MellitusEUCTR2014-005153-39-BGexicon Pharmaceuticals, Inc.750
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s DiseaseModerately to severely active Crohn's diseaseMedDRA version: 18.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-022760-12-BEJanssen-Cilag International N.V.1,310
进行中（未招募）
1 期
Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic MigraineEpisodic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-002397-39-DEAmgen Inc.456
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Adjuvant Radiotherapy and Chemotherapy (RT/CT)Oral mucositisEUCTR2004-002016-28-ESAmgen Ltd315
进行中（未招募）
1 期
Chemoradiotherapy +/- pembrolizumab in participants with MIBCMuscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-004023-20-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.636